arrowband ultraviolet B phototherapy for the treatment of pruritus induced by chronic liver disease and cholestasis

Phase 3

• Conditions: chronic liver disease or cholestasis including chronic hepatitis, cirrhosis, PSC, and PBC; chronic liver disease; D006521

• Registration Number: JPRN-jRCTs052180032
• Lead Sponsor: Takai Atsushi

Brief Summary

Although statistical analysis was difficult because only two subjects were studied, one showed improvement of pruritic symptoms with narrowband UVB therapy, but one did not show long-term control and had flare-ups of symptoms after the end of irradiation.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-01-29
• Study Completion: 2022-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

Patients eligible for preregistration were those: (i) with
chronic liver disease or cholestasis including chronic hepatitis, cirrhosis, PSC, and PBC; (ii) who were at least 20 years of age at the time of
informed consent; (iii) mean VAS>50 mm in one week, or VAS of >20 mm on 5 or more days per week, or pruritus scores >3 on 4 or more days per week.

Exclusion Criteria

Patients with psychiatric disorder, dementia, dermatosis, or chronic renal disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified